Novo Nordisk, once Europe’s most valuable company, is grappling with substantial financial setbacks, shedding nearly 900 billion kronor in market value recently. This decline, exacerbated by heightened competition in the weight loss drug market and regulatory uncertainties, poses significant economic risks for Denmark.
Renowned for drugs like Ozempic and Wegovy, Novo Nordisk reported a second-quarter operating profit of 33.45 billion Danish kronor (50.13 billion Swedish kronor), slightly missing expectations. Despite a 13% year-on-year sales increase to 76.86 billion Danish kroner, the figures fell short of analyst forecasts.
The primary blow came when Novo Nordisk revised its profit outlook downward, citing intensified competition from Eli Lilly in the US obesity treatment market. This move triggered a sharp decline in stock value, plummeting over 50% since the year began.
The fallout extends beyond corporate boardrooms, impacting Danish households with small savers collectively losing approximately 60 billion Swedish kronor in a single day, according to Sydbank estimates.
Such financial upheaval casts a shadow over Denmark’s economic prospects, with Nykredit revising GDP growth estimates downward to 0.9% for the year, down from a previous forecast of 3.5%. Meanwhile, export expectations have also been slashed, predicting a decline of 1.9% in 2025 instead of the earlier anticipated growth of 3.9%.
The broader implications are stark: diminished growth prospects may strain public finances, exacerbate trade imbalances, and dampen innovation and employment rates crucial for national prosperity.
Adding to the company’s woes are uncertainties surrounding US tariff policies and pricing pressures from the Trump administration’s recent demands for lower drug prices.
In response to these challenges, Novo Nordisk has appointed a new CEO, signalling a strategic pivot amidst turbulent times.